Related Experiment Video
Updated: May 28, 2026
09:00
Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
Published on: June 24, 2020
Interleukin-18 in Allergic Diseases-Pathogenesis and Therapeutic Targeting.
Li Tian1,2, Juanjuan Li2, Yun Hu1,2
1Department of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, Guangdong, China.
Summary
Interleukin-18 (IL-18) plays a dual role in allergic diseases, promoting inflammation via mast cells and basophils despite its association with Th1 responses. Targeting the IL-18 pathway offers a novel therapeutic strategy for allergic conditions.
Area of Science:
- Immunology
- Allergy Research
- Cytokine Biology
Background:
- Allergic diseases like asthma and eczema are increasing globally.
- Aberrant immunoglobulin E (IgE) and T helper 2 (Th2) cell responses drive these conditions.
- Interleukin-18 (IL-18) is a cytokine involved in immune responses.
Purpose of the Study:
- To review the current understanding of IL-18 in allergic diseases.
- To detail IL-18's origins, activation, and signaling.
- To evaluate IL-18's impact on immune cells and therapeutic potential.
Main Methods:
- Literature review synthesizing current research on IL-18.
- Analysis of IL-18's role in innate and adaptive immunity.
- Evaluation of IL-18's effects on mast cells, basophils, and Th1/Th2 cells.
Main Results:
- IL-18, while linked to Th1 responses, promotes allergic inflammation.
- IL-18 enhances mast cell and basophil maturation and function, particularly with IL-2.
- IL-18 processing and signaling pathways are crucial for its bioactivity.
Conclusions:
- IL-18 is a key modulator in allergic immunopathology.
- Targeting the IL-18 axis presents a promising therapeutic avenue for allergic diseases.
- Further research into IL-18 pathways can uncover new treatment strategies.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...